Exact Sciences Corporation (EXAS) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $104.91. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of EXAS = $2,183.66 (+1981.5% from the current price, the stock appears undervalued). Analyst consensus target is EXAS = $103 (-1.6% upside).
Valuation: EXAS trades at a trailing Price-to-Earnings (P/E) of -95.7 (S&P 500 average ~25).
Financials: revenue is $3.2B, +16%/yr average growth. Net income is $208M (loss), growing at -85.6%/yr. Net profit margin is -6.4% (negative). Gross margin is 69.7% (-2.7 pp trend).
Balance sheet: total debt is $2.5B against $2.4B equity (Debt-to-Equity (D/E) ratio 1.05, moderate). Current ratio is 2.43 (strong liquidity). Debt-to-assets is 43%. Total assets: $5.9B.
Analyst outlook: 22 / 41 analysts rate EXAS as buy (54%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 35/100 (Fail), Growth 48/100 (Partial), Past 0/100 (Fail), Health 50/100 (Partial), Moat 71/100 (Pass), Future 38/100 (Fail), Income 10/100 (Fail).
